Navigation Links
Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
Date:9/13/2012

AMSTERDAM and IRVINE, Calif., Sept. 13, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Clinical Oncology (ASCO) 2012 Breast Cancer Symposium. The meeting will be held from September 13-15, 2012 at the Marriott Marquis in San Francisco, California. 

Agendia's Symphony™ suite of molecular diagnostic breast cancer tests, which have been available in an FFPE format since January of this year, enable physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers.

Agendia's lead product, MammaPrint®, is the first and only diagnostic breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). Agendia's product development pipeline includes a further extension of its breast cancer Symphony suite as well as similar molecular diagnostic products for colon cancer. 

All of the abstracts listed below can currently be found online at www.ASCO.org. Presentation details are as follows (all times are in Pacific Time). 

Thursday, September 13, 2012

1. Poster Presentation: Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.

  • Lead Author: G. Viale, L. Slaets, F. De Snoo, L. J. van 't Veer, E. J. Rutgers, J. Bogaerts, L. Stork-Sloots, K. Engelen, L. Russo, P. Dell'Orto, F. Cardoso, M. J. Piccart-Gebhart
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall

2. Poster Presentation and Discussion: Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients. 

  • Lead Author: K. Yao, M. Turk, K. Kaul, J. Weaver, F. De Snoo, L. Stork-Sloots, M. Cristofanilli
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall 
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

3. Poster Presentation and Discussion: Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping by MammaPrint and BluePrint. 

  • Lead Author: S. Gluck, F. De Snoo, J. Peeters, G. Somlo, L. Stork-Sloots, L. J. van 't Veer
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

4. Poster Presentation and Discussion: Central review of discordant samples for microarray based on ER, PR and HER2 and local IHC/FISH assessment worldwide from 827 patients. 

  • Lead Author: J. Wesseling, C. Tinterri, A. Sapino, F. Zanconati, M. Lutke Holzik, B. Nguyen, K. B. Deck, P. Querzoli, T. Perin, C. Giardina, G. Seitz, J. –M. Guinebretiere, J. Barone, T. Watanabe, F. De Snoo, L. Stork-Sloots, P. Cusumano
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

5. Poster Presentation and Discussion: Gene expression panel (TheraPrint) analyzed as predictors of response to neo-adjuvant chemotherapy (NCT) in patients (pts) with stage II-III and inflammatory breast cancer (BC). 

  • Lead Author: G. Somlo, F. De Snoo, J. Peeters, L. Stork-Sloots, I. Simon, K. Robinson
  • Presentation Time: 11:00 AM – 1:00 PM; 5:30 PM – 7:00 PM; Location: Golden Gate Hall
  • Discussion Time: 4:30 PM – 5:30 PM; Location: Yerba Buena Ballroom, Salon 8

About Agendia
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact:

Post+Beam
Melissa Hurley
Tel: +1 646 442 2773
E-mail: hurley@postandbeam.is 


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
4. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- US medical equipment and supply demand is forecast to ... Medical Equipment & Supplies: United States , a ... in demand for medical services – driven in large ... by gains in disposable personal income – will boost ... will also drive sales as providers and patients seek ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... 2017 Pace Analytical, a company of over 2,000 employees and a ... acquired ESC Lab Sciences, further solidifying their position as the top American owned ... ... CEO of Pace Analytical ... of Mt Juliet, TN , enhances Pace Analytical,s capability as ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... USHEALTH Group, Inc. ... the prestigious CEO World Awards®. The coveted annual CEO World Awards program encompasses ... case studies, corporate social responsibility, and milestones from every major industry in the ...
(Date:7/24/2017)... ... ... Engineers at the University of Maryland have invented an entirely new kind ... that the body uses. , In ordinary batteries the electrical energy, or current, ... the battery is generated by moving positive ions from one end to the other ...
(Date:7/24/2017)... Kansas City, MO (PRWEB) , ... July 24, 2017 , ... ... for the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... an interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Cosmetic Town, an ... and the cosmetic surgeries they perform on a daily basis. , The new ... surgery procedures they specialize in at their practices. , When asked about the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon ... for a unique opportunity that helps high school girls succeed in STEM programs ... Opportunities.” Horizon Goodwill will host over 20 high school girls at their ...
Breaking Medicine News(10 mins):